Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.
Reuters has ranked the top 100 universities across the world, putting Stanford University at the top and naming KU Leuven as the most innovative institution in Europe.
Massachusetts Institute of Technology has unveiled an incubator that will provide funding, space and expertise to boost commercialisation activities on and off-campus.